RE:RE:ban2401 comparisonIt is interesting to read all the press about Roche ph3 failure announcement, which is predicted by the promis hypothesis, as being a negative result for biogen. Lots of skepticism due to many plaque targeting failures.
Yes, we want biogen to have partial success, thereby setting up pmn. My question is more about why aducanumab is used as our benchmark rather than ban2401, given that ban2401 appears to be slightly better between the two, based on recent presentations and reports.
Dr Goldstein verbally indicated that the two are basically similar. I would just like to see some dot blot and spr data if they have it.
I am still all in on pmn and a huge fan. Just trying to do all the due diligence I can.